Background: Mycetoma is a distinct flesh eating and destructive neglected tropical disease. It is endemic in many tropical and subtropical countries. Mycetoma is caused by bacterial infections (actinomycetoma) such as Streptomyces somaliensis and Nocardiae or true fungi (eumycetoma) such as Madurella mycetomatis. Until date, treatments fail to cure the infection and the available marketed drugs are expensive and toxic upon prolonged usage. Moreover, no vaccine was prepared yet against mycetoma.
Introduction:
Mycetoma is a distinct flesh eating and a devastating neglected tropical disease, caused by bacterial infections (actinomycetoma) such as Streptomyces somaliensis and Nocardiae or true fungi (eumycetoma) such as Madurella mycetomatis [1, 2] . Mycetoma is endemic in many tropical and subtropical countries, these regions are referred to as the "mycetoma belt" that lies between 15 o S -30 o N of the equator [3 -6] . Sudan is considered as one of the most affected regions by this disease, furthermore 70% of the prevalence causes of mycetoma is related to Madurella mycetomatis [6 , 2, 5] . The disease characterized by chronic subcutaneous masses, large tumor-like swellings, multiple draining sinuses, discharge grains, blood and pus; while the recurrent infection may lead to amputation [7, 8, 9, 10, 11] . The infection is mainly located in the lower extremities, but could also affect other parts of the body [5, 6] . Mycetoma can affect all age groups years) and is more common in males than females with a ratio 3:1. It is widely spread within people who had lived in rural areas and had worked in the farms due to their frequent contact to/with organisms, which have saprobiotic life in soil. In other hand, man to man infection does not occur [4] . There are no ideal diagnostic tools available to identify mycetoma and the identification of the etiological agent is a very challenging issue that reflects directly on the treatment, especially in non-endemic areas [9, 12] . In the other hand treatment is not affordable, not effective, toxic for patients and requires a long period (18-24 months or more) [8, 9] . No vaccine was prepared yet against mycetoma therefore, vaccination is highly recommended [13] . In a study done by Nele de Klerk et al, presents two antigenic proteins that have the ability to induce an antibody response in human fructose-bisphosphate aldolase (FBA) and pyruvate kinase (PK) of M. mycetomatis that might be useful as vaccine-candidates in the prevention of mycetoma [10] .
The aim of the study is to predict effective epitope-based vaccine against fructose-bisphosphate aldolase (FBA) enzymes of M. mycetomatis. Development in immunogenetics will enhance apprehension of the impact of genetic factors on the interindividual and interpopulation variations in immune responses to vaccines that could be helpful for progress new vaccine strategies [14] . In silico / reverse vaccinology had replaced conventional-culture based vaccine because it reduces the cost required for laboratory investigation of pathogen, also speeds up the time needed to achieve the results [15] . Therefore, using immunoinformatics approaches to predict this new kind of vaccines could be a magnificently additive in the way forward of preventing mycetoma. Normally, the investigation of the binding affinity of antigenic peptides to the MHC molecules is the main goal when predicting epitopes. Using such tools and information leads to the development of new vaccines [15, 16] . While these approaches permit the optimization of a vaccine for a specific population, the problem can also be reformulated to design a 'universal vaccine': a vaccine that provides maximum coverage on the whole worlds' population [17] . In this study we focused on both MHC class II & I with performing of molecular docked in HLA-A0201.
Results:

3.1.B-cell epitope prediction
The sequence of Fructose-bisphosphate aldolase [Madurella mycetomatis] was subjected to Bepipred lin epitope prediction, Emini surface accessibility and Kolaskar and Tongaonkar antigenicity methods in IE to determine the binding to B cell, being in the surface and to test the immunogenicity. The results w shown in Table ( 
Prediction of T helper cell epitopes and interaction with MHC II alleles
Core Sequence Alleles Number of alleles
Fructose-bisphosphate aldolase physical and chemical parameters:
The physicochemical properties of Fructose-bisphosphate aldolase (FBA) protein was assessed us BioEdit software version 7.0.9.0. The protein length was found to be 363 amino acids and the molec weight was 39675.83 Daltons. The amino acid that formed FBA protein and their number along with t molar percentage (Mol%) were shown in table (4) . 
Population Coverage Analysis
Population coverage test was performed to detect all epitopes binds to MHC1 alleles, MHC11 alleles for Sudan and North Africa. 
Discussion
The current study reveled three promising peptides that could be the first vaccine against Fruc bisphosphate aldolase madurella mycetomatsis worldwide. The peptide KYLQ is the only peptide passed all B-cell prediction tests which used in this study and show high binding affinity in docking.
MHC 71 conserved peptides were predicted using (ANN) method with (IC50) there were 240 predicted peptides found to interact with MHC-II alleles. We proposed the peptides FFKEHGVPL, IYQALSKIS and YIRAVAPIY that had the affinity to bind the highest number of MHC11 FEYARKHAF and FFKEHGVPL were proposed as potential candidates to be devolved in to a vaccine.
Herein, in-silico molecular docking was done to explore the binding affinity between the aforementioned peptides and the target HLA-A0201. This target has been selected for docking pertained with its involvement in several immunological and pathological diseases hence, although numerous studies have demonstrated an association between HLA alleles and disease susceptibility, Defining protective HLA allelic associations potentially allows the identification of pathogen epitopes that are restricted by the specific HLA alleles. These epitopes may then be incorporated into vaccine design in the expectation that the natural resistance can be replicated by immunization [36, 37, 38] . The binding energies between the peptides and HLA-A0201 molecule were calculated and ranked. Peptide FFKEHGVPL shows the best Docking result, this indicates a strong potential to formulate a vaccine utilizing the peptide FFKEHGVPL that is highly promising to be the first proposed epitope-based peptide vaccines against Fructose-bisphosphate aldolase (FBA) of Madurella mycetomatis. Based on our previous studies on Mokola Rabies Virus and Lagos Rabies Virus, a computational analysis was made and the most immunogenic epitopes for T and B cells involved in the cell-mediated immunity were analyzed [39] [40] . In this study the same techniques were used, to design the as target proteins [41, 42] . But we believe that fructose-bisphosphate aldolase (FBA) enzymes could be the best target protein due to its high ability to induce an antibody response in a human. In Nele de Klerk et al study, they found that both FBA and PK IgG antibodies were present in eumycetoma patients' sera. However, only FBA antibody levels were found to be significantly higher in eumycetoma patients' sera when compared to healthy controls [10] .
Conclusion
To the best of our knowledge this study is consider to be the first to propose epitope-based peptide vaccine against Fructose-bisphosphate aldolase (FBA) of Madurella mycetomatis, which is expected to be highly antigenic with a minimum allergic effect. Furthermore, this study proposes promising peptides of (KYLQ) that show a very strong binding affinity to B-cell, (FEYARKHAF) with a very strong binding affinity to (MHC1) alleles and (FFKEHGVPL) that shows a very strong binding affinity to (MHC11) and (MHC1) alleles. In-vivo and in-vitro assessment for the most promising peptides namely; (KYLQ), (FEYARKHAF) and (FFKEHGVPL) are recommended to be explored and find out more on their ability to be developed into vaccines against Madurella mycetomatis. 
